Ekso Bionics Holdings, Inc. Q1 FY2022 Earnings Call

· Earnings call transcript and AI-powered summary

Quarter Overview

  • Q1 2022 revenue was 2.6 million dollars, up 34 percent from 1.9 million dollars in Q1 2021. Growth was driven by higher EVO (industrial) sales and recognition of prepaid royalties.
  • Leadership highlighted strong momentum entering 2022 across both EksoHealth and EksoWorks, following a record Q4 2021.
  • The company continues to deepen relationships with large network operators and expand its industrial presence.

Segment Highlights

EksoHealth

  • Generated 1.9 million dollars in revenue, similar to the strong levels last seen in Q2 2021.
  • Booked 23 EksoNR units during Q1, the largest multi‑unit order activity in company history.
  • Approximately 50 percent of these bookings were capital purchases and 50 percent subscription agreements.
  • Ten of the 23 booked units are included in Q2 backlog due to supply chain impacts.
  • Ekso reported an 82 percent cumulative conversion and renewal rate and over 1.5 million dollars of contracted but unrecognized subscription revenue, expected to be recognized over the coming months.
  • International performance:
    • Europe: strong performance driven by improved sales proficiency.
    • APAC: developing pipeline with expectations for meaningful contribution later in 2022.

EksoWorks (Industrial)

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide.: Operator: 00:06 Greetings. Welcome to the Ekso Bionics First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. Please note, this conference is being recorded. 00:25 I will now turn the call over to your host, Andrew Blazier of Finn Partners. Thank you. You may begin. Andrew Blazier: 00:31 Thank you, Devin and thank you all for participating in today's call. Joining me from Ekso Bionics are Steven Sherman, Chairman and Chief Executive Officer; Scott Davis, President and Chief operating Officer; and Jack Glenn, Chief Financial Officer. Earlier today, Ekso Bionics released financial results for the quarter ended March 31, 2022. A copy of the press release is available on the company's website. 00:58 Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional